Injectable Bulking Agents for Fecal Incontinence
Dextranomer microspheres in non-animal stabilized hyaluronic acid (NASHA Dx, marketed as Solesta) is the only FDA-approved injectable bulking agent for fecal incontinence and should be your first-line injectable option when conservative measures and biofeedback therapy have failed. 1
When to Consider Injectable Bulking Agents
Injectable bulking agents are positioned in the treatment algorithm after:
- Conservative therapies (dietary modification, fiber supplementation, loperamide for diarrhea, bowel training) have been optimized for at least 3 months
- Pelvic floor biofeedback therapy has been attempted
- Patients remain symptomatic with passive fecal incontinence
The guideline explicitly recommends perianal bulking agents such as intraanal injection of dextranomer when conservative measures and biofeedback therapy fail. 1
Evidence for NASHA Dx (Solesta)
The pivotal randomized, double-blind, sham-controlled trial demonstrated:
- 52% of patients (71/136) in the active treatment group achieved ≥50% reduction in fecal incontinence episodes at 6 months, compared to 31% (22/70) in the sham group (OR: 2.36; P = 0.0089) 1
- Most patients (82%) required a second injection for optimal results 1
- Benefits persisted at 12 and 24 months, with approximately 64% and 63% maintaining response, respectively 1
- Patients experienced significantly more incontinence-free days and improved quality of life in coping and behavior domains 1
Safety Profile
Common adverse events include:
- Proctalgia (14%)
- Fever (8%)
- Rectal bleeding (7%)
- No migration, protrusion, or leakage of material was observed 1
Real-world data from a 17-patient cohort showed 82.3% success after first treatment, with 41% achieving complete continence at final follow-up 2. The procedure is technically straightforward and safely performed as an outpatient under direct anoscopic visualization 2.
Important Caveats
The mechanism of action remains unclear—dextranomer did not significantly increase anal resting or squeeze pressures and was not superior to biofeedback therapy in head-to-head comparison 1. This suggests the benefit may be through enhanced anal canal seal rather than functional sphincter improvement.
Other Bulking Agents (Not FDA-Approved for FI)
While various materials have been studied, including:
- Carbon-coated zirconium oxide beads (Durasphere)
- Polydimethylsiloxane elastomer (PTQ)
- Autologous fat
- Synthetic calcium hydroxylapatite
None of these have FDA approval for fecal incontinence 3, 4. A Cochrane review found most trials had methodological weaknesses, and only NASHA Dx demonstrated superiority over sham injection 3.
Clinical Algorithm Position
Injectable bulking agents sit between conservative/biofeedback therapy and more invasive options (sacral nerve stimulation, sphincteroplasty, artificial sphincter, or colostomy) in the treatment hierarchy 1. They are particularly appropriate for patients with passive incontinence who want to avoid or are not candidates for more invasive procedures.
Before proceeding with injection, ensure anorectal testing (manometry and imaging with endoanal ultrasound or MRI) has been performed to characterize sphincter anatomy and exclude large sphincter defects (>120°), which may be better served by alternative interventions 1.